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Abstract
Background: Repeat radiation is a rarely used treatment strategy that must be performed with caution. The
efficacy and toxicity of a second curative radiotherapy series was investigated in cases of recurrent breast cancer.
Methods: Forty-two patients treated from 1993 to 2003 with resection (n = 30) and postoperative re-irradiation or
definitive re-irradiation (n = 12) for recurrent breast cancer were enrolled in the study. Concurrent hyperthermia
was performed in 29 patients. The median age was 57 years. The median pre-radiation exposure was 54Gy. Re-
irradiation was conventionally fractionated to a median total dose of 60Gy.
Results: After a median follow-up of 41 months (range 3-92 months) higher graded late toxicity > G3 according to
CTC 3.0 and LENT-SOMA was not observed. The estimated 5-year local control rate reached 62%. The estimated 5-
year overall survival rate was 59%. Significantly inferior survival was associated with recurrence within two years (40
vs. 71%, p < ([0-9]).01) and presence of macroscopic tumour load (24 vs. 75%, p = 0.03).
Conclusions: Repeat radiotherapy for recurrent breast cancer with total radiation doses of 60 Gy and the addition
of hyperthermia in the majority of patients was feasible, with acceptable late morbidity and improved prognosis,
particularly in patients with previous resection of recurrent tumours.
Background
Treatment of pre-radiated regions remains a therapeutic
challenge for breast cancer, particularly as the curative
potential of local (surgery, radiotherapy) and systemic
(anti-hormonal therapy, chemotherapy) treatment of
loco-regional recurrences has yet to be elucidated [1,2].
After treatment with breast-conserving surgery and
radiotherapy, the standard procedure is to carry out sal-
vage mastectomy for in-breast recurrences [3]. In highly
selected patients with in-breast tumours (< 3 cm, no
skin or chest wall infiltration, cN0, cM0) a skin sparing
mastectomy with immediate breast reconstruction is a
possible treatment option with a local control rate of
90% [4]. In contrast, in lesser selected series, mastect-
omy for invasive recurrences causes local control to
drop to 68-87% [5].
Treating chest wall recurrences after mastectomy with
re-surgery alone provides limited local control for one-
third of patients [6]. The routine addition of a second
radiotherapy series is accompanied by major concerns
regarding side effects, as cumulative radiation doses
reach or exceed 100 Gy, which may lead to an increased
rate of late complications. However, combined treat-
ment of chest wall recurrences i.e. excision plus irradia-
tion revealed superior local control of 48 vs. 34% after
five years in single institution series [7]. For irresectable
recurrences, re-irradiation combined with additional
hyperthermia enhanced efficacy i.e. local control com-
pared to radiotherapy alone by approximately 20% [8,9].
On the basis of the results from these prospective trials,
thermoradiotherapy has become a standard treatment
for patients with irresectable recurrent lesions particu-
larly those in previously irradiated areas.
No definitive trial investigating the options of re-treat-
ment i.e. re-irradiation +/- re-surgery has been carried
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mentioned concerns. Unequal pre-radiation exposure
(40-70 Gy) would lead to considerable different risks of
late effects within the studyp o p u l a t i o na n dd i s t o r t
results. Therefore, this retrospective study was per-
formed to evaluate the long-term results and toxicity of
local treatment by re-irradiation +/- preceding macro-
scopically complete resection with curative intent.
Furthermore, this analysis focused on tumour- and
treatment-related parameters to optimize management
of breast cancer recurrences in the future.
Methods
Between 1993 and 2003, 42 women with locoregional
recurrent breast cancer were treated with a macroscopi-
cally complete resection plus subsequent re-irradiation
of the chest wall (n = 30) or definitive radiotherapy (n =
12) at the University of Tübingen.
For inclusion in this retrospective analysis, patients
had to fulfill the following criteria: All patients had been
initially treated for invasive breast cancer using mastect-
omy or breast conserving surgery, both combined with
adjuvant radiotherapy of the whole breast or the chest
wall including regional lymphatics, or a radiation boost
if indicated. Patients with preceding or simultaneous
metastases, new primary tumours unrelated to their
breast cancer or receiving palliative treatment were
excluded. The patients fulfilling these criteria were iden-
tified by the departmental database. After discussing the
intended analysis, the institutional review board (Ethik-
kommision der Medizinischen Fakultät, Gartenstrasse
47, 72074 Tübingen) had no objections (Nr. 116/2011A).
A brief summary of the clinical characteristics at first
diagnosis of breast cancer is provided in Table 1. The
first session of radiotherapy was carried out using 6 MV
photons with tangential fields or 4-12 MeV electrons
with one/multiple fields or an electron rotation. Gamma
irradiation with cobalt 60 was rarely administered. Field
definitions were standard definitions of the treatment
time as published by Sack and Thesen [10]. The median
pre-radiation exposure was 54 Gy.
In-breast recurrences were treated by mastectomy.
Chest wall recurrences were removed by local excision-
if possible. Re-irradiation was not routinely performed
in cases of resected recurrence as an “adjuvant” proce-
dure. Preconditions of individual re-irradiation were
close (≤0.5 cm) or positive margins, perinodal involve-
ment, multiple recurrences or other high-risk features
explaining a number of recurrences totaling five until
re-irradiation was administered.
Details regarding second treatments and the course of
disease at the time of recurrence are displayed in Table
2. The median time to local recurrence calculated from
the first radiotherapy session was 33 months and ranged
between 9 and 400 months. The median time between
the two radiation courses was 53 months. Re-irradiation
was conventionally fractionated with single doses of 1.8-
2.0 Gy five times/week (in one individual case 4 × 2.5
Gy/week), resulting in a median total dose of 60 Gy,
Table 1 Tumour- and treatment characteristics at initial
diagnosis.
Characteristic at initial diagnosis Value
Patients (n) 42
Year of first treatment
Median 1992
Range 1968-2002
Age (y)
Range 30-66
Median 49
pT-stage (n)
x1
11 5
21 7
37
42
pN-status (n)
axillary lymph node dissection 41
node-negative 22
node-positive 19
unknown 1
pR-status (n)
R0 31
R1 7
R2 1
Rx 3
Grading (n)
I5
II 23
III 9
unknown 5
Hormone receptor expression (n)
ER-positive 21
PR-positive 19
unknown 3
Surgery of primary breast cancer (n)
Mastectomy 18
Breast conserving surgery 24
Radiation treatment of primary breast cancer(n)
Adjuvant total radiation breast/chest wall dose (Gy)
Median 54
Range 40-65.4
Lymph node irradiation 25
Systemic treatment of primary breast cancer (n)
Chemotherapy 24
Hormonal treatment 10
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women. Regional lymphatics (supra-/infraclavicular
fossa, and if indicated parasternal or axillary nodes)
were covered by radiation portals in 15 patients (36%)
to a median total dose of 50 Gy. Parasternal nodes were
irradiated in seven patients (17%) using the mixed-
beam-technique. Re-irradiation was performed using 6
MV photons (n = 24) with tangential fields or 4-12
MeV electrons with an electron beam rotation technique
(n = 18) as described elsewhere [11]. Chestwall was
defined as thoracic wall extending from the second to
the sixth/seventh intercostal space including a small
portion of the underlying lung. Longitudinal field bor-
ders were orientated to the position of the contralateral
breast (inferior/superior margin 2 cm below palpable
contralateral breast; the contralateral breast was not
irradiated.). Medial margin was 1 cm over midline. Lat-
eral margin was usually near midaxillary line. Resulting
mean re-irradiation field size was 17 × 17 cm (ranging
from 8 × 8 cm to 35 × 20 cm). In most cases, the whole
chestwall was covered (n = 34) according to the above
mentioned target volume definition. Eight patients were
treated with involved field techniques with a lateral mar-
gin of ≥3 cm. The brachial plexus and regional lympha-
tics were not re-irradiated.
In cases of close or positive margins and definitive
treatment, superficial radiofrequency hyperthermia was
offered as an additional modality, leading to concurrent
application in 29 patients (69%). Almost all patients
with microscopically positive margins received
hyperthermia (n = 14; 88%), while after R0-resection (n
= 8; 57%) or in cases of inoperable recurrences (n = 7;
58%), approximately three-fifths of patients received
hyperthermia. Superficial hyperthermia was performed
with the SA-115 applicator twice a week using a
BSD2000 hyperthermia system operating at a frequency
between 210-219 MHz. Median hyperthermia time was
75 min, i.e. 5-15 min heating period and at least 60 min
treatment time (steady state of temperature). The target
temperature was a minimum of 40°C and measured at
the skin.
Hyperthermia was performed in accordance with the
ESHO-Guidelines. A detailed description of hyperther-
mia with SA-115 has been published [12]. Further treat-
ment before or after repeat radiotherapy consisted of
sequential chemotherapy or hormonal therapy (Table 2).
After re-treatment, senological examinations were per-
formed every three to six months during the first two
years and every six to twelve months thereafter. These
investigations included clinical examination and imaging
if required. Patients were monitored at least annually in
terms of toxicity by a radiation oncologist. The Patient’s
records and questionnaires were reviewed with respect
to radiation-induced side effects. Acute radiation
dermatitis was investigated during and after re-irradia-
tion and documented according to CTC 3.0. Late toxi-
city was defined as side effects occurring three months
after treatment. Radiation dermatitis, induration/fibrosis,
teleangiectasia, pericarditis, pericardial effusion and
Table 2 Patient characteristics at second radiation
course.
Characteristic at diagnosis of recurrence Value
Patients (n) 42
Age (y)
Median 57
Range 33-75
Time to first recurrence (months)
Median 33
Range 9-400
Number of recurrences until re-irradiation
12 3
21 3
more than 2 (range) 6 (3-5)
Site of recurrence (n)
Chest wall 31
In-breast recurrence 8
Regional nodal 3
Surgery of recurrence preceeding re-irradiation (n)
Mastectomy 9*
Local excision 22
Inoperable 11
pR-status for operable patients (n)
R0 14
R1 16
R2 1
Re-Radiation treatment of recurrence
Total radiation chest wall dose (Gy)
Median dose 60
Range 45-66
Lymph node irradiation (n) 15
#
Cumulative radiation dose (Gy)
Median dose 110
Range 85-126
Concurrent hyperthermia (n) 29
Photons (n) 24
Electrons (n) 18
Time between both radiation courses (months)
Median 53
Range 12-401
Systemic treatment of recurrent breast cancer (n)
Sequential chemotherapy 17
Hormonal treatment 19
*15 Salvage mastectomies were performed at first recurrence explaining the
lower number of mastectomies at time of re-irradiation.
#Lymph node irradiation was normally restricted to sites initially not irradiated,
i.e. axillary nodes.
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addition, side effects related to skin (fibrosis/teleangiec-
tasia) and lung (fibrosis) were documented according to
LENT-SOMA[13].
Local failure was defined as any recurrence of tumour
in the ipsilateral chest wall or in mastectomy scars.
Regional failure was defined as any recurrence of
tumour in the ipsilateral regional nodes. Recurrence at
any other site was considered as distant failure. Time to
any failure until re-irradiation was defined as the time
from definitive surgery to the time of diagnosis of the
first failure. Time to any failure after the second radia-
tion course was defined as the time from start of re-irra-
diation, in order to compare patients with and without
excision.
Local control, distant-disease-free survival, disease-free
survival and overall survival were the main endpoints,
and these were calculated from time of re-irradiation
using the Kaplan-Meier method [14]. Further subgroup
analyses were performed for local control and overall
survival. Initial tumour parameters (nodal stage, estro-
gen receptor status, time to first recurrence (≤2 years vs.
> 2years), number of recurrences until re-irradiation
(one vs. more than one)), surgery of recurrence, margin
status, concurrent hyperthermia, lymph node irradiation,
sequential chemotherapy and anti-hormonal therapy
were investigated as factors. Actuarial curves were com-
p a r e du s i n gt h et w o - t a i l e dl o g - r a n kt e s t .Ap - v a l u eo f
≤0.05 was considered significant. Statistical analyses
were performed using the software package SPSS 15.0
(SPSS Inc., Chicago, Illinois, USA).
Results
The median follow-up from second radiation treatment
was 41 months (range 3-92 months). One patient was
lost to follow-up. For the 28 surviving women, the med-
ian follow-up reached 48 months. With respect to total
dose, patients completed radiation treatment as planned.
For one patient, a treatment break of two weeks was
required owing to acute radiation dermatitis. Concurrent
hyperthermia was offered to all patients but some had
contraindications (thrombosis, cardiac insufficiency and
hypertension) and others refused hyperthermia, leading
to an omission rate of 31%. Hyperthermia was com-
pleted as planned in 72% of patients (n = 21/29). In two
patients, the number of planned hyperthermia treat-
ments was not given. In six patients, the duration of one
hyperthermia treatment in each case was shorter than
60 min. Repeat radiotherapy was performed at first
recurrence in median but 19 patients experienced at
least two recurrences until re-irradiation was adminis-
tered. Therefore, the median time to second radiother-
apy (53 months) was 20 months longer than time to
first recurrence (Table 2).
Local and distant control and disease-free and overall-
survival are presented in Figure 1a-d. The estimated
five-year local control reached 62% (n = 32/42). Local
failures occurred in 10 patients (R0: 3/14, R1: 3/16; R2/
irresectable: 4/12). All patients with irresectable disease
achieved a clinical complete remission for at least three
months in the re-treated area.
Endocrine therapy increased local control (93 vs. 31%,
p = 0.01). However, local control decreased significantly
from 91% to 31% (p = 0.02) if at least two recurrences
were experienced before re-irradiation was administered.
A time period of less than two years to the first recur-
rence (< 2 years vs. ≥2years: 16 vs. 68%, p = 0.14) did
not significantly lower local control. However, long-term
local control at last follow-up improved to 70% (n = 35/
42) owing to curative resections of recurrences after re-
irradiation in three patients. In one of the three patients
additional brachytherapy was performed to a total dose
of 30 Gy. A sub-analysis of concurrent hyperthermia for
R1-resected patients revealed a prolonged local control
(86 vs. 50%, p = 0.19; with one salvage treatment after
re-irradiation 93 vs. 50%, p = 0.05) but this was not sig-
nificant. No other investigated factors significantly
affected local control (data not shown).
The estimated five year overall survival of patients was
59%. Estimated overall survival was significantly shor-
tened in patients who had not undergone surgery of
recurrence (75 vs. 24%, p = 0.03), Figure 2a. Clear resec-
tion margins (R0) led to significantly prolonged overall
survival in contrast to gross residual disease (80% vs.
29%, p = 0.0448). A trend to improved overall survival
was observed for patients with R1-resection compared
with patients with macroscopical residual disease, Figure
2b (69 vs. 29%, p = 0.06). Concurrent hyperthermia was
associated by an increase of overall survival (67 vs. 37%,
p = 0.27) but this was not significant.
Furthermore, the relevance of tumour-related para-
meters was investigated. Significantly poorer overall sur-
vival was detected in women (n = 15) where a time
period of less than two years had passed before the first
recurrence (71 vs. 40%, p < 0.01), Figure 2c. A trend to
reduced overall survival was evident in women who had
not been re-irradiated at first recurrence (75 vs. 43%; p
= 0.11). Re-irradiation at second recurrence (n = 13)
resulted in the lowest estimated survival curve with 34%
overall survival compared to 75% overall survival at first
recurrence (n = 23) (p = 0.08, data not shown). A trend
to inferior survival was observed for initially node-posi-
tive patients (73 vs. 41%, p = 0.06), Figure 2d. Grading
did not significantly lower outcome (G1 vs. G3: 80% to
37%, p = 0.37).
Regional (n = 3) and distant (n = 12) metastases mani-
fested in 15 patients.. The mean distant disease-free sur-
vival time exceeded more than five years (68 months,
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months). The mean disease-free survival was reached
before 5 years (54 months, CI: 41-67 months).
No treatment related deaths occurred. Acute and late
skin toxicity of radiation schedules are documented in
Table 3. Grade 2 acute skin reactions of were doubled
(12 vs. 25 patients) at the second radiotherapy session
while acute grade 3 toxicity was inversely distributed
(five vs. two patients). Grad e2a n d3l a t es k i nt o x i c i t y
of was elevated by approximately 12% after repeat irra-
diation (G2: 50 vs. 62%; G3:7 vs. 19%). Radiation-
induced pneumonitis was observed after re-irradiation
in four patients (twice grade 1 and 2) in contrast to one
case of pneumonitis (grade 1) during the first radiation
course. One patient developed rib-fractures. Brachial
plexopathy, or pericarditis related to treatment were not
observed. Therefore, no patient experienced toxicity
higher than grade 3.
Discussion
Local breast cancer recurrences are a therapeutic chal-
lenge with respect to available treatment options, mor-
bidity and toxicity. Depending on the risk features, local
recurrence might further herald distant metastasis [15].
The optimal treatment procedures have been debated
for at least two decades [2,16,17]. The complexity of
treatment increases, particularly in patients who have
previously undergone radiotherapy, as total re-treatment
doses below 55 Gy produce poor local control rates
without hyperthermia [18]. However the expectation of
late effects of higher cumulative doses limits the second
treatment. Therefore, this analysis concerning re-irradia-
tion to a median total dose of 60 Gy could facilitate a
balanced treatment decision.
This series clearly demonstrates that the best long-
term local control was achieved in patients treated with
a combined schedule i.e. surgery and re-irradiation
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Figure 1 Local control and survival parameters. Local control (a), distant disease-free survival (b), disease-free survival (c) and overall survival
were estimated using the Kaplan-Meier-method after a median follow-up of 41 months. The parameters were calculated from time of re-
irradiation for recurrence.
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Page 5 of 8predominately performed with hyperthermia and com-
bined with anti-hormonal treatment. Reducing the risk
of local relapse using endocrine therapy is in line with
findings concerning primary treatment of breast cancer
[19,20]. Eighty percent of secondary recurrences after
re-treatment occur within two years [21]. Therefore it is
assumed that another recurrence is unlikely, and this
assumption is supported by a median follow-up time of
48 months for survivors. Regarding the estimated five
year overall survival rate of 75% in the combined
a) Overall survival and surgery
c) Overall survival and time to recurrence d) Overall survival and nodal involvement
b) Overall survival and resection margin
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Figure 2 Impact of treatment- and tumour-related parameters on overall survival. Overall survival was significantly influenced by surgery
of recurrence (a) and resection margin (b). R0-resection led to prolonged overall survival in contrast to patients with gross residual disease (80%
vs. 29%, p = 0.04). Furthermore, time to first recurrence less than two years was associated with a significant detrimental effect on overall survival
(c). A trend to prolonged overall survival was detected in patients without nodal involvement at initial diagnosis of breast cancer (d). All
parameters were calculated from time of re-irradiation for recurrence.
Table 3 Acute and late skin toxicity.
CTC-Grade Acute skin toxicity Late skin toxicity
1st radiotherapy 2nd radiotherapy 1st radiotherapy 2nd radiotherapy
02 0 4 1
1 2 11 5 1 47
2 1 22 5 2 12 6
35 2 3 8
40 0 0 0
unknown 2 0 0 0
The treatment-related cumulative cutaneous side effects were graded according to CTC 3.0 and documented for both radiation courses. Since the first radiation
treatment was performed before the definition of CTC criteria, all data from medical charts were reviewed and converted into CTC 3.0 criteria to compare
maximal occurred cumulative toxicity at first and second radiation courses. Maximal cumulated late toxicity of the first radiation course was assessed at last
follow-up before treatment or at baseline examination before re-treatment.
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Page 6 of 8treatment group, it is concluded that durable local con-
trol results in improved prognosis.
In 1999, the working group reported a three year local
control rate of 80% for complete resections of breast
cancer recurrences (most without pre-radiation) after a
radiation schedule of 4 × 2.5 Gy/week to a total dose of
50 Gy. This resulted in local control of only 37% for R1/
2-resections despite an additional boost to a total radia-
tion dose of 60 Gy [22]. To intensify radiotherapy, con-
current hyperthermia was introduced leading to 81%
local control after three years for marginally excised
patients [23]. This series focused on a very unfavourable
and rare subset of patients defined by breast cancer
recurrence plus previous irradiation. Therefore, this ana-
lysis concerns a small number of patients with updated
follow-up of the last mentioned investigation. However,
even in cases of re-irradiation and dose compromise, for
exceptional patients (R0-resection of recurrence plus
pre-radiation exposure of 60 Gy) the referred local con-
trol rate could be replicated.
Probably as a result of manifold and overlapping para-
meters and small sample size of subgroups, local control
and survival parameters were improved, but not signifi-
cantly, by concurrent hyperthermia in this series. The
role of hyperthermia after R0-resection remains unclear
in this retrospective series. However, it can be assumed
that additional hyperthermia compensated for positive
margin (R1).
In the unfavourable situation of no surgical options,
patients have the greatest incremental gain in complete
response by additional hyperthermia according to a
recently published randomized trial (23.5% vs. 68.2%)
[24]. A pooled analysis of five poorly recruited rando-
mized trials addressed this issue and estimated a 59%
CR-rate for thermoradiotherapy compared with 41% for
irradiation alone. Similarly, the greatest benefit was
observed in patients with recurrent lesions in previously
irradiated areas [8]. The data are comparable with the
reported local control rates of other re-irradiation series
+/-hyperthermia with 24-75% [5,7-9,25-28]. Further-
more, hyperthermia doubled overall survival (n.s.) in
patients with residual disease.
A recently published multi-institutional review of re-
irradiation achieved a 53% 1-year-disease-free survival
for unresected patients. Hyperthermia and chemother-
a p yw e r ea p p l i e ds i m u l t a n e o u s l yt om o r et h a nh a l ft h e
women with a median total dose reaching 48 Gy [5].
Patients with gross residual disease did not receive addi-
tional chemotherapy in this study but did receive a
higher median radiation dose. The calculated 1-year and
estimated 5-year-disease-free survival of patients with
gross residual disease were in the same range, 46% and
28%, respectively.
The only significant tumour-related parameter for
overall survival was time below two years to first recur-
rence. This finding has been substantiated by others
[17,29]. A trend to better survival for initially node-
negative patients demonstrates the lower aggressiveness
of the disease [30]. Favourable results could arise from
the young median age of the patient population.
Younger patients are more frequently affected by iso-
lated recurrences [31]. This fact explains why re-surgery
was possible and why the distant failure rate was rela-
tively low compared to other studies [15].
In this series, one of the highest reported median re-
irradiation- and cumulative radiation dose was adminis-
tered. Owing to a conventionally fractionated regimen
acute and early late toxicity was moderate as indicated
by late effects not exceeding grade 3. This observation is
consistent with other retrospective series that reach
lower cumulative doses [27,32]. However, pronounced
late toxicity was observed with a hypofractionated proto-
col for excised patients consisting of 2 × 4 Gy/week to a
total dose of 32 Gy plus weekly hyperthermia. Fourty
percent experienced late toxicity ≥grade 3 after three
years [33]. Originally, this protocol was developed for
palliation [34,35]. Nineteen percent (n = 8) grade 3
fibrosis and one case of rib fracture were detected after
a median follow-up of 41 months. To evaluate late
effects such as brachial plexopathy or cardiac failure
further observation is required.
Conclusions
Standard treatment for breast cancer recurrences is sur-
gical resection, if possible. In general, owing to the detri-
mental effect of recurrences, early re-irradiation is
recommended at first recurrence and a fortiori in case
of recurrence within two years, as both factors were
associated with dramatically reduced local control and
overall survival.
Repeat radiotherapy for breast cancer recurrence, with
total radiation doses of 60 Gy and the addition of
hyperthermia in the majority of patients is feasible. This
treatment has acceptable late morbidity and results in
improved prognosis particularly in patients who have
undergone previous resection of the recurrence.
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